biostudies-literatureHsia DSNCATS NIH HHSCenters for Disease Control and PreventionNIDDK NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesAmerican Diabetes AssociationNational Institutes of HealthNational Heart Lung and Blood InstituteNIGMS NIH HHS108692https://www.ebi.ac.uk/biostudies/studies/S-EPMC10923170biostudies-literatureUnknown38(3)Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143.Journal of diabetes and its complicationsThe incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).PMC10923170UL1 TR002378UM1 TR004528UL1 TR002537UL1 TR001425UL1 TR002535UL1 TR000439UL1 TR001108UL1 TR001449UL1 TR001409P30 DK020572U01DK098246P30 DK020541–44U34-DK-088043UL1 TR0022432UL1TR001425P30 DK092926UL1 TR002489UL1 TR002345UL1 TR002548P30 DK017047U54 GM104940UL1 TR000445UL1 TR002529U34 DK088043P30 DK072476U01 DK098246P30 DK079626P30 DK020541Kassem LSKrause-Steinrauf HGRADE Research GroupYounes NHsia DSfalseThe incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5 years (3.7 %; 184 of 4098 participants) and did not differ among the 4 treatment groups (glargine 4.0 %, glimepiride 3.2 %, liraglutide 3.7 %, sitagliptin 3.8 %). There were no differences in retinopathy with specific therapies in GRADE. Clinicaltrials.gov identifier: NCT01794143.2024-01-01T00:00:00Z2024 Mar2026-06-02T10:23:45.642Z2025-04-07T07:47:23.164ZS-EPMC109231703835448110.1016/j.jdiacomp.2024.108692